#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should recognize cannabinoid hyperemesis syndrome (CHS) as a distinct clinical entity in frequent cannabis users presenting with severe, cyclic nausea and vomiting, as early identification can prevent unnecessary invasive diagnostic workups and guide appropriate management through cannabis cessation. Understanding the dose-dependent disruption of endocannabinoid-mediated nausea regulation helps clinicians counsel patients on the paradoxical risk that chronic high-potency cannabis use carries for severe emetic symptoms, despite cannabis’s known acute antiemetic properties. This knowledge is critical for emergency departments and primary care settings where CHS patients frequently present, as misdiagnosis leads to delayed treatment and repeated hospitalizations that could be
Cannabinoid Hyperemesis Syndrome (CHS), colloquially termed “scromiting,” represents a paradoxical adverse effect in chronic heavy cannabis users characterized by severe nausea, vomiting, and compulsive hot bathing that provides temporary relief. The syndrome is thought to result from chronic cannabinoid overstimulation of the endocannabinoid system, which disrupts the body’s natural homeostatic control of nausea and vomiting, with evidence suggesting a dose- or duration-dependent threshold effect before symptom onset. Clinicians should maintain awareness of CHS as a diagnosis in heavy cannabis users presenting with recurrent vomiting unresponsive to conventional antiemetics, particularly those with paradoxical symptom improvement during hot showers or baths. The condition typically resolves only with complete cannabis cessation, though symptom management during acute episodes may include supportive care, topical capsaicin, and benzodiazepines for severe cases. Practitioners should screen for CHS in patients using high-potency cannabis products or engaging in frequent consumption, as early recognition can prevent unnecessary diagnostic workup and inappropriate antiemetic escalation. Counseling patients about the risk of CHS, particularly those considering long-term cannabis use for chronic conditions, represents an important aspect of informed consent and harm reduction in cannabis medicine.
“Cannabinoid Hyperemesis Syndrome is real and we’re seeing it more frequently in clinical practice, particularly in patients using high-potency products daily, and the paradox is that many come in already convinced cannabis is their solution when it’s actually the cause. Once I establish the diagnosis and patients stop using cannabis, the relief is typically dramatic within days, which both confirms the mechanism and underscores why we need better patient education about dose and frequency thresholds.”
🤢 The association between heavy cannabis use and cannabinoid hyperemesis syndrome (CHS) has become increasingly recognized in clinical practice, though the underlying mechanism remains incompletely understood and likely involves dysregulation of the endocannabinoid system’s role in nausea and vomiting control. Providers should be aware that CHS typically emerges in chronic, high-frequency users and may present diagnostically challenging because initial symptoms can mimic gastroenteritis or other gastrointestinal disorders, leading to unnecessary workup and delayed recognition. Important confounders include the potency and route of cannabis use (with higher-THC products and dabbing appearing more closely associated), patient genetics affecting endocannabinoid metabolism, and possible interactions with other medications or comorbid conditions that affect nausea pathways. When taking a substance use history in patients with recurrent nausea and vomiting, particularly those unresp
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: